An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and DOCA-salt hypertensive rats

Journal of Autonomic Pharmacology
D W DaltonP P Humphrey

Abstract

The actions of intravenously administered 5-hydroxytryptamine (5-HT) have been analysed in conscious DOCA-salt hypertensive rats using selective 5-HT receptor agonists and antagonists to determine the receptor mechanisms involved and to compare them with those in conscious normotensive rats. In both normotensive and hypertensive rats 5-HT, 3 and 10 micrograms i.v., produced a complex triphasic effect on blood pressure consisting of an initial short lasting depressor response, which was followed by a pressor response and then, finally, a hypotensive phase. Marked decreases in heart rate were observed immediately after dosing, which were followed by small increases in rate. The selective 5-HT3-receptor agonist, 2-methyl 5-HT, 3-30 micrograms i.v., produced immediate and marked dose-related decreases in blood pressure and heart rate in both normotensive and DOCA-salt hypertensive rats. The 5-HT3-receptor antagonist, MDL 72222, 0.03 and 0.1 mg/kg i.v., antagonised these effects in both normotensive and DOCA-salt hypertensive rats. Treatment with MDL 72222, 0.3 mg/kg i.v., abolished the initial depressor response and bradycardia produced by 5-HT. The 5-HT2 receptor agonist, alpha-methyl 5-HT, 3-30 micrograms i.v., produced dose-rela...Continue Reading

References

Jan 1, 1985·Journal of Cardiovascular Pharmacology·P M Vanhoutte
Jul 1, 1985·Hypertension·P NeedlemanD G Standaert
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·G Haeusler, L Finch
Jan 1, 1973·Physiological Reviews·A S Paintal
Sep 1, 1970·The American Journal of Physiology·D D McGregor, F H Smirk
Aug 1, 1982·The Journal of Pharmacy and Pharmacology·P P HumphreyA D Watts
Sep 1, 1982·Journal of Cardiovascular Pharmacology·J R Fozard
Jul 30, 1984·Life Sciences·M A TrevethickP P Humphrey
May 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Fozard
Nov 1, 1984·Hypertension·T E Mecca, R C Webb
Dec 9, 1983·European Journal of Pharmacology·W FeniukA D Watts
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·G FeuersteinI J Kopin
Jul 1, 1960·Journal of Applied Physiology·V POPOVIC, P POPOVIC

❮ Previous
Next ❯

Citations

Sep 22, 1989·European Journal of Pharmacology·H DabiréH Schmitt
Mar 24, 1995·European Journal of Pharmacology·G BalasubramaniamS C Mah
May 1, 1989·Trends in Pharmacological Sciences·P R Saxena, M D Ferrari
Mar 13, 2012·Pharmacological Reviews·Stephanie W WattsSusan M Barman
Aug 1, 1990·Acta Physiologica Scandinavica·P A Hedberg, D L Rutlen
Feb 19, 2015·Pharmacology Research & Perspectives·Stephanie W WattsJanice M Thompson
Jan 1, 1989·Fundamental & Clinical Pharmacology·P R Saxena
May 4, 2010·Cardiovascular Therapeutics·Stephanie W Watts, Robert Patrick Davis
May 28, 2019·Physiological Genomics·Bridget M SeitzStephanie W Watts
Sep 3, 2013·Biological & Pharmaceutical Bulletin·Shuji GamohRyuichi Yamamoto
Apr 16, 2005·Clinical Science·Stephanie W Watts
Jun 20, 2017·American Journal of Physiology. Heart and Circulatory Physiology·Bridget M SeitzStephanie W Watts
May 23, 2000·Journal of the American Society of Nephrology : JASN·Jennifer M GrossFranklyn G Knox
Jul 13, 2021·Frontiers in Physiology·Bridget M SeitzGregory D Fink
May 25, 2021·Journal of Cardiovascular Pharmacology·Romina Gonzalez-PonsStephanie W Watts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.